| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L E Rueter, P Blie. Electrophysiological examination of the effects of sustained flibanserin administration on serotonin receptors in rat brain. British journal of pharmacology. vol 126. issue 3. 1999-05-27. PMID:10188973. |
the responsiveness of postsynaptic 5-ht1a receptors located on ca3 hippocampus pyramidal neurons and mpfc neurons, examined using microiontophoretically-applied 5-ht and gepirone, was unchanged following a 7-day flibanserin treatment. |
1999-05-27 |
2023-08-12 |
rat |
| M A Riddle, G A Bernstein, E H Cook, H L Leonard, J S March, J M Swanso. Anxiolytics, adrenergic agents, and naltrexone. Journal of the American Academy of Child and Adolescent Psychiatry. vol 38. issue 5. 1999-05-25. PMID:10230186. |
to review extant data on the efficacy and safety of anxiolytic medications (benzodiazepines, buspirone, and other serotonin 1a agonists), adrenergic agents (beta-blockers and alpha 2-adrenergic agonists clonidine and guanfacine), and the opiate antagonist naltrexone that have been used to treat various psychopathologies in children and adolescents. |
1999-05-25 |
2023-08-12 |
Not clear |
| A W Wilson, J C Neill, B Costal. An investigation into the effects of 5-HT agonists and receptor antagonists on ethanol self-administration in the rat. Alcohol (Fayetteville, N.Y.). vol 16. issue 3. 1999-05-24. PMID:9744857. |
the number of responses and ethanol reinforcers (dipper deliveries), ethanol consumption (g/kg of body weight), and locomotor activity (lma) were measured following administration of 5-ht agonists (5-ht, d-fenfluramine, fluoxetine, buspirone, tfmpp, and doi) and antagonists (metergoline, ritanserin, and ondansetron) 30 min prior to testing. |
1999-05-24 |
2023-08-12 |
rat |
| H Okazawa, F Yamane, P Blier, M Diksi. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. Journal of neurochemistry. vol 72. issue 5. 1999-05-06. PMID:10217280. |
effects of acute and chronic administration of the serotonin1a agonist buspirone on serotonin synthesis in the rat brain. |
1999-05-06 |
2023-08-12 |
rat |
| H Okazawa, F Yamane, P Blier, M Diksi. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. Journal of neurochemistry. vol 72. issue 5. 1999-05-06. PMID:10217280. |
the effects of acute and chronic administration of buspirone, a serotonin 5-ht1a agonist, on the 5-ht synthesis rates in various rat brain structures were investigated using alpha-[14c]methyl-l-tryptophan (alpha-[14c]mtrp) and an autoradiographic method. |
1999-05-06 |
2023-08-12 |
rat |
| H Okazawa, F Yamane, P Blier, M Diksi. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. Journal of neurochemistry. vol 72. issue 5. 1999-05-06. PMID:10217280. |
a single dose of buspirone induced a significant decrease of 5-ht synthesis throughout the brain with the exception of the pineal body. |
1999-05-06 |
2023-08-12 |
rat |
| H Okazawa, F Yamane, P Blier, M Diksi. Effects of acute and chronic administration of the serotonin1A agonist buspirone on serotonin synthesis in the rat brain. Journal of neurochemistry. vol 72. issue 5. 1999-05-06. PMID:10217280. |
however, the chronic treatment with buspirone did not induce significant differences in 5-ht synthesis in the brain. |
1999-05-06 |
2023-08-12 |
rat |
| S Andronati, V Sava, S Makan, G Kolodee. Synthesis of 3-aryl-1-[(4-phenyl-1-piperazinyl)butyl]indazole derivatives and their affinity to 5-HT1A serotonin and dopamine D1 receptors. Die Pharmazie. vol 54. issue 2. 1999-04-29. PMID:10084155. |
generally, the presence of the 3-aryl-indazole fragment in the new buspirone analogues increased their affinity to dopamine receptors and reduced their affinity to serotonin receptors. |
1999-04-29 |
2023-08-12 |
Not clear |
| J T Apter, L A Alle. Buspirone: future directions. Journal of clinical psychopharmacology. vol 19. issue 1. 1999-04-07. PMID:9934947. |
since then, numerous studies have examined the efficacy and safety of buspirone for patients with not only generalized feelings of anxiety, but also panic disorder, major depressive disorder, obsessive-compulsive disorder, body dysmorphic disorder, social phobia, posttraumatic stress disorder, selective serotonin reuptake inhibitor-induced adverse events, dementia, behavioral disturbances, attention deficit-hyperactivity disorder, and tobacco dependency. |
1999-04-07 |
2023-08-12 |
Not clear |
| S F de Boer, M Lesourd, E Mocaer, J M Koolhaa. Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635. The Journal of pharmacology and experimental therapeutics. vol 288. issue 3. 1999-04-01. PMID:10027850. |
the present study characterized the effects of the novel, selective, and potent 5-hydroxytryptamine1a (serotonin) (5-ht1a) receptor agonist, alnespirone [s-20499, (s)-n-4-[5-methoxychroman-3-yl)propylamino)butyl- 8-azaspiro-(4,5)-diacetamide, hydrochloride] on offensive and defensive resident-intruder aggression in wild-type rats and compared its actions with those of the prototypical full 5-ht1a agonist 8-hydroxy-2- dipropylaminotetralin (8-oh-dpat), the partial 5-ht1a agonists ipsapirone and buspirone, and the mixed 5-ht1a/1b agonist eltoprazine. |
1999-04-01 |
2023-08-12 |
rat |
| T S Lamberg, K T Kivistö, J Laitila, K Mårtensson, P J Neuvone. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. European journal of clinical pharmacology. vol 54. issue 9-10. 1999-03-26. PMID:9923581. |
the effects of fluvoxamine, a selective serotonin (5-ht) reuptake inhibitor antidepressant, on the pharmacokinetics and pharmacodynamics of buspirone, a non-benzodiazepine anxiolytic agent, were investigated. |
1999-03-26 |
2023-08-12 |
Not clear |
| R F Anto. Neurobehavioural basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol and alcoholism (Oxford, Oxfordshire). Supplement. vol 31. issue 1. 1999-02-25. PMID:9845037. |
because there is considerable co-morbidity between alcohol dependence, anxiety, and affective disorders, results from studies of medications used to treat these psychiatric disorders are also reviewed, including the 5-ht agonist buspirone and the noradrenergic agent desipramine. |
1999-02-25 |
2023-08-12 |
human |
| E C Dimitriou, C E Dimitrio. Buspirone augmentation of antidepressant therapy. Journal of clinical psychopharmacology. vol 18. issue 6. 1999-02-18. PMID:9864079. |
of the 22 patients who had buspirone added to their selective serotonin reuptake inhibitor antidepressant regimen (fluoxetine, paroxetine, or citalopram), 59% (13/22) showed complete or partial remission of their depressive symptomatology. |
1999-02-18 |
2023-08-12 |
Not clear |
| P J Winsauer, F H Rodriguez, A E Cha, J M Moerschbaeche. Full and partial 5-HT1A receptor agonists disrupt learning and performance in rats. The Journal of pharmacology and experimental therapeutics. vol 288. issue 1. 1999-02-05. PMID:9862788. |
as a means of characterizing the role of 5-hydroxytryptamine (5-ht1a) receptors in learning, a full 5-ht1a receptor agonist, 8-hydroxy-dipropylaminotetralin (8-oh-dpat), was administered both alone and in combination with two partial agonists (buspirone and 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl] piperazine hydrobromide (nan-190)) and a 5-ht1a receptor antagonist (p-mppi) to rats responding under a multiple schedule of repeated acquisition and performance of response sequences. |
1999-02-05 |
2023-08-12 |
rat |
| M Landén, G Björling, H Agren, T Fahlé. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. The Journal of clinical psychiatry. vol 59. issue 12. 1999-01-29. PMID:9921700. |
case reports and open studies have reported beneficial therapeutic effects of adding buspirone to a selective serotonin reuptake inhibitor (ssri) in the management of treatment-refractory depression. |
1999-01-29 |
2023-08-12 |
Not clear |
| F Lechin, B van der Dijs, H Jara, B Orozco, S Baez, M Benaim, M Lechin, A Lechi. Effects of buspirone on plasma neurotransmitters in healthy subjects. Journal of neural transmission (Vienna, Austria : 1996). vol 105. issue 6-7. 1999-01-26. PMID:9826102. |
at doses which correlate with dopaminergic stimulation, but not 5-ht inhibition, buspirone also increases the firing rates of the central noradrenergic cells. |
1999-01-26 |
2023-08-12 |
human |
| F Lechin, B van der Dijs, H Jara, B Orozco, S Baez, M Benaim, M Lechin, A Lechi. Effects of buspirone on plasma neurotransmitters in healthy subjects. Journal of neural transmission (Vienna, Austria : 1996). vol 105. issue 6-7. 1999-01-26. PMID:9826102. |
buspirone significantly increased levels of noradrenaline, dopamine, and free serotonin but did not affect levels of adrenaline, tryptophane, or platelet serotonin. |
1999-01-26 |
2023-08-12 |
human |
| F Lechin, B van der Dijs, H Jara, B Orozco, S Baez, M Benaim, M Lechin, A Lechi. Effects of buspirone on plasma neurotransmitters in healthy subjects. Journal of neural transmission (Vienna, Austria : 1996). vol 105. issue 6-7. 1999-01-26. PMID:9826102. |
atropine administration before buspirone ingestion annulled the free serotonin increase as well as systolic blood pressure-heart rate decrease. |
1999-01-26 |
2023-08-12 |
human |
| F Lechin, B van der Dijs, H Jara, B Orozco, S Baez, M Benaim, M Lechin, A Lechi. Effects of buspirone on plasma neurotransmitters in healthy subjects. Journal of neural transmission (Vienna, Austria : 1996). vol 105. issue 6-7. 1999-01-26. PMID:9826102. |
in addition, buspirone increases free serotonin plasma concentrations and decreases systolic blood pressure plus heart rate levels through mechanisms associated with parasympathetic activation. |
1999-01-26 |
2023-08-12 |
human |
| N Haddjeri, P Blier, C de Montign. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 18. issue 23. 1998-12-18. PMID:9822768. |
however, after long-term treatment with the tricyclic antidepressant imipramine, the selective 5-ht reuptake inhibitor paroxetine, the reversible monoamine oxidase-a inhibitor befloxatone, the alpha2-adrenergic antagonist mirtazapine, or the 5-ht1a receptor agonist gepirone or multiple electroconvulsive shock (ecs) administration, way 100635 markedly increased (60-200%) the firing activity of ca3 pyramidal neurons. |
1998-12-18 |
2023-08-12 |
rat |